Parkman Healthcare Partners’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Parkman Healthcare Partners’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-59,943	Closed	-$1.22M	–	99
2022 Q4	$1.22M	Sell	59,943 -16,587	-22%	-$254K	0.32%	70
2022 Q3	$823K	Buy	76,530 +898	+1%	+$10.2K	0.23%	77
2022 Q2	$907K	Buy	75,632 +43,075	+132%	+$695K	0.33%	61
2022 Q1	$697K	Buy	32,557 +1,266	+4%	+$33.5K	0.2%	72
2021 Q4	$1.05M	Buy	31,291 +1,291	+4%	+$36K	0.23%	75
2021 Q3	$772K	Buy	+30,000	New	+$536K	0.2%	69

Parkman Healthcare Partners's OPNT Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 59,943 shares — an estimated $1.22M sold.

Parkman Healthcare Partners first reported a position in OPNT in Q3 2021 and held it in 6 quarters. The position peaked at $1.22M in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Parkman Healthcare Partners reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 59,943 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $1.22M.
Parkman Healthcare Partners first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Parkman Healthcare Partners's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $1.22M in Q4 2022.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.